Vaxcyte, Inc.

Contributing Author

Recent Articles by Vaxcyte, Inc.

Apr-07	Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference PCVX GlobeNewswire
Mar-23	Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults PCVX GlobeNewswire
Mar-18	Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate PCVX GlobeNewswire
Feb-24	Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PCVX GlobeNewswire
Feb-11	Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines PCVX GlobeNewswire
Feb-10	Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 PCVX GlobeNewswire
Feb-05	Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit PCVX GlobeNewswire
Feb-02	Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PCVX +7.15% GlobeNewswire
Jan-29	Vaxcyte Announces Pricing of $550 Million Public Offering PCVX GlobeNewswire
Jan-29	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants PCVX GlobeNewswire
Jan-22	Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine PCVX +7.19% GlobeNewswire
Dec-08	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults PCVX GlobeNewswire
Nov-04	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study PCVX GlobeNewswire
Sep-30	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services PCVX GlobeNewswire
Sep-03	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose PCVX GlobeNewswire
Aug-06	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) PCVX -9.06% PCVX GlobeNewswire
May-07	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update PCVX +8.45% PCVX GlobeNewswire
May-01	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors PCVX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)